Go Pro
OTCMKTS:SHEZF

Shenzhen Hepalink Pharmaceutical Group (SHEZF) Stock Price, News & Analysis

$0.47 0.00 (0.00%)
As of 08/14/2026

About Shenzhen Hepalink Pharmaceutical Group Stock (OTCMKTS:SHEZF)

Advanced

Key Stats

Today's Range
$0.42
$0.47
50-Day Range
$0.47
$0.47
52-Week Range
$0.47
$0.47
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
6.79
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is a China-based pharmaceutical company specializing in the research, development, manufacturing and sale of heparin and related products. The company’s core product line centers on heparin sodium APIs (active pharmaceutical ingredients), low-molecular-weight heparins (LMWH) and specialty heparin derivatives. In addition to bulk heparin APIs, Hepalink produces a range of finished dosage forms such as heparin injections and protamine sulfate, serving hospitals, distributors and pharmaceutical companies.

Since its founding in the late 1990s in Shenzhen, Hepalink has grown to become one of the world’s leading suppliers of heparin and LMWH. The company operates multiple GMP-certified manufacturing facilities in China and holds regulatory approvals from major markets, including China’s NMPA, the U.S. FDA and the European Medicines Agency. Hepalink exports its products to more than 80 countries and regions, with significant markets in North America, Europe, Asia and Latin America, where it supports both generic and specialty anticoagulant therapies.

Beyond heparin APIs and formulations, Hepalink has expanded its R&D capabilities to include recombinant proteins, monoclonal antibodies and other biologics. The company collaborates with academic institutions and international partners to advance novel drug candidates and optimize production processes. With a focus on quality control, regulatory compliance and innovation, Shenzhen Hepalink continues to invest in research facilities and process development to support long-term growth in both domestic and global pharmaceutical markets.

AI Generated. May Contain Errors.

Receive SHEZF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Shenzhen Hepalink Pharmaceutical Group and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SHEZF Stock News Headlines

The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
See More Headlines

SHEZF Stock Analysis - Frequently Asked Questions

Shenzhen Hepalink Pharmaceutical Group's stock was trading at $0.4696 at the beginning of 2026. Since then, SHEZF shares have increased by 0.0% and is now trading at $0.4696.

Shares of SHEZF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
OTCMKTS:SHEZF
CIK
N/A
Fax
N/A
Employees
2,080
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
6.79
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

This page (OTCMKTS:SHEZF) was last updated on 8/17/2026 by MarketBeat.com Staff.
From Our Partners